On May 16, 2024, eFFECTOR Therapeutics, Inc. received a notice from Nasdaq's Listing Qualifications Department stating that the company's Minimum Value of Listed Securities (MVLS) has fallen below the required $35 million threshold for continued listing on the Nasdaq Capital Market. This valuation has been under the limit for the past thirty consecutive business days, triggering a potential delisting risk under Nasdaq Listing Rule 5550(b)(2). Despite this notice, eFFECTOR Therapeutics' common stock will remain listed and continue trading on the Nasdaq under the ticker symbol 'EFTR', provided it meets other listing requirements. The company has been granted a 180-day period, until November 12, 2024, to regain compliance with the MVLS requirement. To achieve this, the company's MVLS must close at or above...Show More

On May 16, 2024, eFFECTOR Therapeutics, Inc. received a notice from Nasdaq's Listing Qualifications Department stating that the company's Minimum Value of Listed Securities (MVLS) has fallen below the required $35 million threshold for continued listing on the Nasdaq Capital Market. This valuation has been under the limit for the past thirty consecutive business days, triggering a potential delisting risk under Nasdaq Listing Rule 5550(b)(2). Despite this notice, eFFECTOR Therapeutics' common stock will remain listed and continue trading on the Nasdaq under the ticker symbol 'EFTR', provided it meets other listing requirements. The company has been granted a 180-day period, until November 12, 2024, to regain compliance with the MVLS requirement. To achieve this, the company's MVLS must close at or above $35 million for at least ten consecutive business days within this period. Failure to meet this condition, or to maintain other listing standards such as a minimum stockholders' equity of $2.5 million, could lead to delisting. eFFECTOR Therapeutics is currently exploring options to address the issue and regain compliance, but there is no certainty that it will succeed in maintaining its Nasdaq listing.